Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 74th Scientific Sessions of the American Diabetes Association (ADA)
Oral Therapies Realigned to Provide Improved Control and Reduced Risk in Type 2 Diabetes
San Francisco, California / June 13-17, 2014
San Francisco - New guidance for sustained glycemic control in type 2 diabetes mellitus (T2DM) has been derived from two studies of real-world therapy. Both studies, presented at the ADA, provided insight on long-term glycemic control in...
PHYSICIAN PERSPECTIVE - Get with the PROTOCOL - Dual-antiplatelet Therapies for Acute Coronary Syndromes: A Regional Perspective on the Evidence and Resulting Changes
Hamilton Health Sciences
June 2014
Guest Editor: Madhu Natarajan, MD Interventional CardiologistDirector, Hamilton-Niagara Integrated Heart Investigation Unit Hamilton Health SciencesMcMaster UniversityHamilton, Ontario Introduction The protocol for antiplatelet...
PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from Vascular 2013
SGLT2 Inhibitors: A Multi-Pronged Tool Against Type 2 Diabetes
Montreal, Quebec / October 17-20, 2013
Guest Editors: Philip A. McFarlane, MD, PhD, FRCPCDivision of NephrologySt. Michael’s HospitalUniversity of TorontoToronto, Ontario Ronald M. Goldenberg, MD, FRCPC, FACELMC Diabetes & EndocrinologyThornhill,...
PRIORITY PRESS - Vascular 2013
Revisiting ß-Blockers for the Treatment of Uncomplicated Hypertension
Montreal, Quebec / October 17-19, 2013
Montreal - The Canadian Hypertension Education Program (CHEP) continues to be the only program globally that annually reviews, updates and re-examines the hypertension literature to provide Canadian practicing physicians with optimal...
MEDICAL FRONTIERS - CHEST 2013
Recent Trial Data Foster New Definitions of Optimal Management for Pulmonary Arterial Hypertension
Chicago, Illinois / October 26-31, 2013
Chicago - As a reflection of progress in the treatment of pulmonary arterial hypertension (PAH), experts speaking at the 2013 Chest meeting contend that they consider normalization of right ventricle function a viable therapeutic goal in at...
MEDICAL FRONTIERS - American Heart Association (AHA) Scientific Sessions 2013
New US Guideline for Treatment of Blood Cholesterol for Prevention of Atherosclerotic Cardiovascular Disease
Dallas, Texas / November 16-20, 2013
Dallas - The first public presentation of the latest American College of Cardiology (ACC)/American Heart Association (AHA) practice guidelines took place during a special plenary session at the AHA Scientific Sessions 2013. The new...
PRIORITY PRESS - Vascular 2013
Hyponatremia in Heart Failure: Addressing Sodium and Symptoms
Montréal, Québec / October 16-20, 2013
Montreal - Hyponatremia develops in up to 30% patients with heart failure (HF). The condition may be chronic and largely asymptomatic but may worsen during episodes of acute decompensation. The significant negative impact of low serum...
MEDICAL FRONTIERS - European Respiratory Society (ERS) Annual Congress 2013
New Treatment Options in Pulmonary Arterial Hypertension Appear to Move Treatment Goals Beyond Symptom Control
Barcelona, Spain / September 7-11, 2013
Barcelona - New data presented at the ERS 2013 from trials published just weeks before the meeting was convened, document a paradigm shift in the treatment of pulmonary hypertension. In pulmonary arterial hypertension, the benefit of a new...
PRIORITY PRESS - 35th Annual Congress of the European Society of Cardiology (ESC)
Vascular Outcomes Trials Confirm Safety of DPP-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Amsterdam, Netherlands / August 31-September 4, 2013
Amsterdam - Both of the first two trials in a series to confirm the cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors met their primary end point. Although there are important differences in the design and information...